MGC Pharmaceuticals (LON: MXC) said the phase 3 clinical trial to evaluate the efficacy and safety of CimetrA as a treatment for hospitalised patients diagnosed with COVID-19 has now commenced following the recruitment of the first patient.
The company’s co-founder and managing director, Roby Zomer, said the trial commencing “is a milestone for both MGC Pharma and the medicinal cannabis industry.”
In total, 252 patients will be enrolled in the double-blind placebo-controlled clinical trial following the CimetrA Investigational Medicinal Product (IMP) production, validation, and ethics committee approval.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
The study’s results will also be submitted to the European Medicines Agency (EMA).
“Testing CimetrA™ as an IMP will have great implications for those suffering with COVID-19 and ensure the risk of healthcare systems becoming overwhelmed is minimised,” said Zomer.
MGC Pharmaceuticals share price is up 2..3% at 2.14p following today’s news.
Should You Invest in MGC Pharmaceuticals Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now